RT Journal Article SR Electronic T1 Tall cell variant papillary thyroid carcinoma in Saudi patients JF Saudi Medical Journal JO Saudi Med J FD Prince Sultan Military Medical City SP 1220 OP 1224 DO 10.15537/smj.2016.11.15480 VO 37 IS 11 A1 Khalid H. Al-Qahtani A1 Mutahir A. Tunio A1 Mushabbab Al Asiri A1 Yasser Bayoumi A1 Walaa A. Alshehri A1 Naji J. Aljohani A1 Ahmed Amir Ali A1 Hanadi Fatani YR 2016 UL http://smj.org.sa/content/37/11/1220.abstract AB Objectives: To evaluate the clinicopathological features and treatment outcomes of papillary thyroid carcinoma tall cell variant (PTC-TCV) in Saudi population.Methods: This retrospective study were medical records of 776 treated PTC patients between December 2007 and 2015, at King Fahad Medical City and King Khalid University Hospital, Riyadh, Kingdom of Saudi Arabia was probed for PTC-TCV. Total 42 (5.4%) patients were found to have PTC-TCV, which were investigated for demographic, symptoms, histopathological features, and treatment outcomes locoregional control (LRC), distant metastasis control (DMC), disease free survival (DFS), and overall survival (OS) rates.Results: Mean age of cohort was 52.3 years (range: 46-80), with female predominance (73.8%). Mean tumor size was 3.62 cm (range: 0.4-10). Rates of LVSI (59.5%), positive pathological lymph nodes (66.7%), multifocality (42.9%) and extrathyroidal extension, (45.3%). Median follow-up was 37.4 months (range: 6-60). Local recurrence rate were seen in 6/42 (14.2%) patients and 8/42 (19%) developed distant metastasis. The 5 year rates of LRC (82.3%), DMC (77.8%), DFS (69.2%), and OS (86.7%) multivariate analysis showed PTC-TVC as an important independent prognosticator (odds ratio: 4.2; 95% confidence interval: 1.79-7.3; p=0.03)Conclusion: Papillary thyroid carcinoma tall cell variant is associated with aggressive biological behavior.